Clinical trials: Dementia Mild
Alzheimer Disease, Dementia
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.
- Trial name
- NCT00322036
- Testing
- MPC-7869
- Where
- 92 sites in United States, Belgium and 10 more
- Volunteers
- 800 people
- Sponsor
- Myrexis Inc.
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Mild Cognitive Impairment
A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this…
- Trial name
- NCT01594541
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Pamlab, Inc.
Alzheimer's Disease
ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)
The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.
- Trial name
- NCT00231946
- Testing
- VP4896
- Where
- 59 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- Voyager Pharmaceutical Corporation
Alzheimer's Disease
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).
- Trial name
- STAR Extension (NCT02079246)
- Testing
- Idalopirdine 60 mg
- Where
- 258 sites in United States, Argentina and 25 more
- Volunteers
- 1,463 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Alzheimer's Disease
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild…
- Trial name
- NCT01397578
- Testing
- MABT5102A
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Alzheimer Disease
Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine whether combination of donepezil, a cholinesterase inhibitor, with choline alfoscerate has a more favourable clinical profile than monotherapy with donepezil alone.
- Trial name
- COALA (NCT05383183)
- Testing
- Choline Alfoscerate 400mg
- Where
- 4 sites in South Korea
- Volunteers
- 630 people
- Sponsor
- Daewoong Bio Inc.
Alzheimer Disease, Dementia
PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
This is a prospective, multicentric, randomized, double blind, placebo controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 therapy along with standard supportive care in subjects with mild to…
- Trial name
- NCT04052737
- Testing
- Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
- Where
- 5 sites in India
- Volunteers
- 80 people
- Sponsor
- Pharmazz, Inc.
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.
- Trial name
- NCT05686044
- Testing
- Buntanetap/Posiphen
- Where
- 54 sites in United States
- Volunteers
- 351 people
- Sponsor
- Annovis Bio Inc.
Alzheimer's Disease
Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT00265148
- Testing
- Rosiglitazone
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Alzheimer's Disease
A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease
The objective of this 3-month study is to assess the safety and efficacy of EHT 0202 in addition to acetylcholinesterase inhibitor in patients suffering from Alzheimer's Disease.
- Trial name
- EHT0202/002 (NCT00880412)
- Testing
- EHT 0202 etazolate
- Where
- 22 sites in France
- Volunteers
- 197 people
- Sponsor
- Exonhit
Alzheimers Disease
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 1 (NCT07169578)
- Testing
- Trontinemab
- Where
- 142 sites in United States, Argentina and 11 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959.
- Trial name
- NCT02560753
- Testing
- T3D-959
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- T3D Therapeutics, Inc.
Dementia, Mild, Cognitive Disorder Mild
The Pilot Study of Medical Device-Neuclare for Patients With Mild Cognitive Disorder and Early Dementia
This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.
- Trial name
- NCT05633095
- Testing
- Neuclare
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Deepsonbio
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine (UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in mild AD patients.
- Trial name
- NCT02551809
- Testing
- UB-311
- Where
- 4 sites in Taiwan
- Volunteers
- 43 people
- Sponsor
- United Neuroscience Ltd.